Inclusion body myositis

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
2 Unique sponsors
2 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Kinase inhibitor 1 substance
Phase III: 1 Phase II/III: 1 Phase II: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • Abcuro Inc. Commercial
    ULVIPRUBART
    2024-517623-39-00 3 countries 2025 n=13 Orphan
    Ended

Phase II/III

1 trial
  • Abcuro Inc. Commercial
    ULVIPRUBART
    2022-501925-19-00 3 countries 2024 n=24 Orphan
    Ended

Phase II

1 trial
  • Assistance Publique Hopitaux De Paris Academic
    RUXOLITINIB
    2023-507666-32-00 1 country 2025 n=80
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Abcuro Inc. Commercial 2 Phase II/III, Phase III 0
Assistance Publique Hopitaux De Paris Academic 1 Phase II 1
New trials by year
2024
1
2025
2
← All indication landscapes